Australasian Anaesthesia 2019

Total Page:16

File Type:pdf, Size:1020Kb

Australasian Anaesthesia 2019 Australasian Anaesthesia 2019 R. RILEY Australasian Anaesthesia 2019 Invited papers and selected continuing education lectures Editor: Richard Riley Department of Anaesthesia and Pain Medicine Royal Perth Hospital Pharmacology and Anaesthesiology Unit School of Medicine and Pharmacology University of Western Australia Contents AIRWAY 1 The Vortex Approach to airway management 3 Nicholas Chrimes Managing airway trauma: Applying logic and structure to the anaesthetic decision-making process 13 Adam Rehak Unanticipated difficult airway events: A systematic analysis of the current evidence and mapping of the issues involved using a Bowtie diagram 25 Yasmin Endlich, Martin Culwick Flexible bougies, introducers and bronchoscopes – Key adjuvants in the Age of Videolaryngoscopes 35 John Cormack, Wallace Grimmett, David Shan BREATHING/VENTILATION 47 Hyperbaric medicine 49 Bridget Devaney CIRCULATION 59 Perioperative management of heart transplantation 61 Sean Edwards, Sara Jane Allen Preventing vascular damage during central venous catheter insertion via the internal jugular vein 75 Jennifer Bath, Andrew Deacon, Alister Jones Keep calm and know sepsis 89 Linden Martyr, Samuel Cook, Siva Senthuran Midodrine and its potential role in postoperative hypotension 101 Verna M Aykanat, Ian O Fleming, Tomás B Corcoran COAGULATION/BLOOD 113 It’s about bloody time! The massive transfusion protocol in trauma 115 Sinéad O’Keeffe, Ray Paramalingam, Christine Grobler Differentiation of preoperative anaemia 127 Hafiza Misran, Hamish Mace, Shane Gangatharan, Kylie Symons REGIONAL 137 An update on the management of patients with rib fractures 139 Andrew Lumley, Sean Chan, Andrew Deacon Parallel processing pathways for regional anaesthesia: An introduction to block rooms 151 ISBN 978-0-9945075-6-3 Brigid Brown, Tim Donaldson Copyright © 2019 by the Australian and Ultrasound-guided erector spinae plane block 157 New Zealand College of Anaesthetists. Alex Grosso, Gilberto Arenas, Kate Drummond, Sam Whitehouse All rights reserved. None of the contents of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means without the prior written permission of the publisher. Please note that any views or opinions expressed in this publication are solely those of the author and do not necessarily represent those of ANZCA. PAIN 167 The “opioid crisis” 169 Stephan A Schug Opioid harm reduction strategies – stemming the tide 175 Michael H Toon The changing face of complex regional pain syndrome treatment 183 Marc Russo, Peter Georgius, Danielle Santarelli BRAIN/NEURO 193 Postoperative delirium 195 Faculty and Regional Editors Kate O’Hare, Silke Brinkmann, Dale Currigan Professor Thomas Bruessel The psychedelic renaissance: Ethnopharmacology, neuroscience and clinical efficacy 203 John Akers Australian Capital Territory High hopes for dope: What role does medicinal cannabis play in current clinical practice? 219 Dr Brenda Cassidy Nilru Vitharana, Jane Standen Faculty of Pain Medicine Anaesthetic implications of restless legs syndrome: A review 227 Nicole Somi, Elizabeth Merenda, Thomas Bruessel Associate Professor Alicia Dennis Victoria LIVER/METABOLIC/IMMUNE SYSTEM 237 Dr Thomas Fernandez Obesity and anaesthesia 239 New Zealand Peter Baumgartner Dr Adrian Langley Euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: Queensland New drugs bring new problems 251 Venkatesan Thiruvenkatarajan, Emily Jane Meyer, Nagesh Nanjappa, John Currie, Dr Priya Nair Roelof M Van Wijk, David Jesudason College of Intensive Care Medicine Anaesthesia and immune modulation 265 Michelle Roets, Melinda Dean, Jaisil EJ Punnasseril, Kerstin Wyssusek, Associate Professor Richard Riley Andre van Zundert, David Sturgess Western Australia OB/GYN 277 Dr Sharon Tivey New South Wales Role of simulation in obstetric anaesthesia training 279 Rebecca A Szabo, Kara Allen, Olivia J Millay Dr Gerald Toh South Australia ASSESSMENT 287 Dr Maurice Vialle Prehabilitation 289 Tasmania Diyana Ishak, Prabir Patel Reifying race in medicine 299 Alan McLintic EDUCATION 311 Human factors in anaesthesia: Beyond non-technical skills 313 Stuart Marshall Feasibility of an open access collaborative anaesthesia knowledge base 319 Ryan Juniper, Agnieszka Ganska MANAGEMENT 325 A resilience engineering approach to out-of-hours healthcare: The SAFE initiative 327 Tim Bowles, Deepan Krishnasivam, Katherine Birkett Preface Welcome to the 2019 edition of Australasian Anaesthesia. This edition has a variety of “hot” topics that I hope you find interesting and relevant to your practice. This is despite several colleagues suggesting to me that the golden age of anaesthesia is over. They argue that the drugs are so good now, the technology is superb and the techniques so well developed that research funding has largely moved away from anaesthesia to other specialties, such as oncology and immunology. The implication is that return on investment in anaesthesia-related pharmaceuticals or equipment is possibly lower than other fields and that we should not expect to witness monumental discoveries in anaesthesia as all the innovation has been largely achieved. Certainly, I feel privileged to have seen the introduction of remifentanil, isoflurane, then followed by sevoflurane and desflurane; the adoption of capnography, oximetry and processed EEG; and the transition from simple mechanical anaesthesia machines to complex, computerised anaesthesia delivery units with integrated monitoring that rival ICU systems. Further, airway management has broadened its armamentarium with the advent of the laryngeal mask airway, videolaryngoscopy and fibreoptic bronchoscopy. Similarly, ultrasound has been adopted by anaesthetists to enhance the practice of regional anaesthesia, vascular access and even airway management and to aid perioperative diagnosis of various crises. And we should not forget the pioneering work of anaesthetists in the hybrid field of simulation in healthcare. Simulation- based learning has contributed to the education of anaesthetists, and all their colleagues in acute-care medicine, and to assist in understanding how we work and, finally, to enhance patient safety. So if I have learned one thing about those who practice anaesthesia it is that they are innovative. Although one age is over, there will be another. There will be better and safer drugs, newer technologies to remove some of the guesswork and enhance decision-making in our practice, and additional strategies to make the perioperative process lower risk. And this will be taking place while facing demands of patients with greater age, body mass index and number of comorbidities; and hospital managers who strive to contain hospital budgets. This is my last edition as editor and I wish to thank the authors, the faculty and regional editors and ANZCA’s Liane Reynolds, Frankie Rowsell and Vanessa Hille for their work and support in producing this edition. Please take the opportunity to thank our authors personally when you can and also consider writing yourself for the next edition. Finally, please continue to give us feedback. This is your publication and we would like to make it better. Associate Professor Richard Riley Editor, Australasian Anaesthesia 2019 [email protected] Airway The Vortex Approach to airway management Nicholas Chrimes Managing airway trauma: Applying logic and structure to the anaesthetic decision-making process Adam Rehak Unanticipated difficult airway events: A systematic analysis of the current evidence and mapping of the issues involved using a Bowtie diagram Yasmin Endlich, Martin Culwick Flexible bougies, introducers and bronchoscopes – Key adjuvants in the Age of Videolaryngoscopes John Cormack, Wallace Grimmett, David Shan The Vortex Approach to airway management 3 The Vortex Approach to airway management Nicholas Chrimes BSc MBBS(Hons) FANZCA Monash Medical Centre, Melbourne, Australia. Dr Nicholas Chrimes is a consultant anaesthesiologist, simulation instructor and the creator of the Vortex Approach. INTRODUCTION While technical competence and adequate planning are crucial to effective airway management, it is well recognised that even well-prepared airway clinicians can sometimes fail to perform basic interventions under stress1. The major airway guidelines are valuable resources that can be referred to prior to the occurrence of an airway crisis, to lay a foundation of knowledge on which subsequent airway management decisions can be based (“foundation tools”). They are not, however, usually presented in a format that makes their content readily accessible in real-time to teams of potentially highly stressed clinicians nor are they intended to be referred to during the process of managing a challenging airway2. In addition, difficult airway guidelines typically provide guidance predominantly directed at anaesthetists and largely restricted to the circumstance where the primary plan for airway management is endotracheal intubation2-4. In contrast, the Vortex Approach5 is based around a “high acuity implementation tool”, designed to be used during the high-stakes, time-critical situation of an evolving airway emergency. It is intended to help clinical teams perform under pressure by providing a simple, consistent template that can be taught to all clinicians involved in advanced airway management, irrespective of critical care discipline and whether they are from a medical, nursing or paramedical background. It is also able to be used in any context
Recommended publications
  • A Model for Mandatory Job Safety Analysis Embedded in the Premit-To-Work System >
    International Gas Union Research Conference 2011 <A MODEL FOR MANDATORY JOB SAFETY ANALYSIS EMBEDDED IN THE PREMIT-TO-WORK SYSTEM > Main author I. K. Yoon KOREA ABSTRACT Permit to Work (PTW) systems is defined as "a formal documented system used to control the certain types of work that are potentially hazardous". Generally, PTW system should be designed to specify the work to be done safely and the precaution to be taken as well as approval, responsibility, permissions of work. For this reason, PTW is regarded as one of the most important safety management system to control the risk of maintenance that causes 30% of the accident in chemical industries. In the early days, PTW was based on paper based system. But recently has continued to evolve into a computer based system. And these advanced systems has been applied to 80% of oil industry in North Sea and upgraded with providing the hazard information as well as supporting documentation. Usually, the hazard information is provided in the form of hazard checklist or attached risk assessment report such as JSA sheet. But when we consider the various types of work, place and environment, all the potential work related hazard cannot be reviewed in the form of prescribed checklist or certain attachment. To review the potential hazard perfectly, the work permit should be supported by Job Safety Analysis (JSA). But it has rarely been seen that company have a rule to require the mandatory JSA whenever permit to work is accomplished. Despite a relatively simple analysis structure, it is time-consuming and person-consuming methodology to complete all the procedure.
    [Show full text]
  • Contingency Planning and Change Management
    CHapteR 11 CONTINGENCY PLANNING AND CHANGE MANAGEMENT Introduction registration agency; for example: changes in Federal and State laws, budget fluctuations, relocation of Change in a voter registration and elections office is election office, staffing changes, agency reorganiza- inevitable, and effective management requires election tion, etc. Unlike contingencies, change management administrators to develop contingency and change focuses on events the office is already aware of and do management plans to respond to situations in a timely not rise unexpectedly. and effective manner. The goal of this chapter is to provide election officials general guidelines on how to identify, assess, and respond to events that may disrupt Identifying and assessing contingencies and election and voter registration services in their local change factors jurisdictions. The chapter addresses both contingency The first step in developing contingency and change planning and change management as they are inextri- management plans is to identify the contingencies cably linked to each other and may at times be devel- and change factors that can impact election and voter oped concurrently with each other. The goal of both registration practices and procedures in your particular these management plans is to prevent or minimize the community. This process is useful for several reasons. impact of change (expected or unexpected) on election First, it will help you define the goal of either your and voter registration processes, while preserving the contingency or change management plans. Second, it integrity of the electoral system. The recommendations will help you to objectively assess situations and their contained in this chapter should be vetted with Federal, potential impact.
    [Show full text]
  • Personal Protective Equipment Hazard Assessment
    WORKER HEALTH AND SAFETY Personal Protective Equipment Hazard Assessment Oregon OSHA Personal Protective Equipment Hazard Assessment About this guide “Personal Protective Equipment Hazard Assessment” is an Oregon OSHA Standards and Technical Resources Section publication. Piracy notice Reprinting, excerpting, or plagiarizing this publication is fine with us as long as it’s not for profit! Please inform Oregon OSHA of your intention as a courtesy. Table of contents What is a PPE hazard assessment ............................................... 2 Why should you do a PPE hazard assessment? .................................. 2 What are Oregon OSHA’s requirements for PPE hazard assessments? ........... 3 Oregon OSHA’s hazard assessment rules ....................................... 3 When is PPE necessary? ........................................................ 4 What types of PPE may be necessary? .......................................... 5 Table 1: Types of PPE ........................................................... 5 How to do a PPE hazard assessment ............................................ 8 Do a baseline survey to identify workplace hazards. 8 Evaluate your employees’ exposures to each hazard identified in the baseline survey ...............................................9 Document your hazard assessment ...................................................10 Do regular workplace inspections ....................................................11 What is a PPE hazard assessment A personal protective equipment (PPE) hazard assessment
    [Show full text]
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • What Chamber Operators Should Know About Ear Barotrauma (And How to Prevent It) Robert Sheffield, CHT and Kevin “Kip” Posey, CHT / June 2018
    LEARN.HYPERBARICMEDICINE.COM International ATMO Education What Chamber Operators Should Know About Ear Barotrauma (and How to Prevent It) Robert Sheffield, CHT and Kevin “Kip” Posey, CHT / June 2018 INTRODUCTION Ear barotrauma (i.e. “ear block”, “ear squeeze”) is the most common complication of hyperbaric treatment. It occurs when the pressure in the hyperbaric chamber is greater than the pressure in the middle ear. It is prevented by patient assessment, patient education, and the appropriate actions of the chamber operator. The chamber operator has an important role in preventing ear barotrauma in hyperbaric patients. OBJECTIVES At the conclusion of this article, the reader will be able to: Describe the anatomy of the middle ear Explain the mechanism of ear barotrauma Describe 3 techniques to equalize middle ear pressure ANATOMY OF THE MIDDLE EAR The middle ear is an air space that separates the external ear canal from the inner ear. The eardrum, called the tympanic membrane (TM), vibrates when sound enters the ear canal. The vibration is transmitted to a series of bones in the middle ear. These bones transmit vibration to another membrane (the oval window) that separates the air‐filled middle ear from the fluid‐filled inner ear, where sound is sensed in the cochlea. The nasopharynx is the area behind the nose and above the palate. The Eustachian tubes open into this area. Because of the location of the Eustachian tube openings, the same things that cause nasal congestion (e.g. allergies, upper respiratory infection) can cause swelling around the opening of the Eustachian tubes, making it more difficult to equalize pressure in the middle ear.
    [Show full text]
  • Laryngospasm Caused by Removal of Nasogastric Tube After Tracheal Extubation: Case Report
    Yanaka A, et al. J Anesth Clin Care 2021, 8: 061 DOI: 10.24966/ACC-8879/100061 HSOA Journal of Anesthesia & Clinical Care Case Report pCO2: Partial pressure of carbon dioxide pO : Partial pressure of oxygen Laryngospasm Caused by 2 mmHg: Millimeter of mercury Removal of Nasogastric Tube mg/dl: Milligram per deciliter mmol/L: Millimole per litter after Tracheal Extubation: Case Introduction Report Background Laryngospasm (spasmodic closure of the larynx) is an airway Ayumi Yanaka1 and Takuo Hoshi2* complication that may occur when a patient emerges from general 1Department of Anesthesiology and Critical Care Medicine, Ibaraki Prefectur- anesthesia. It is a protective reflex, but may sometimes result in al Central Hospital, Japan pulmonary aspiration, pulmonary edema, arrhythmia and cardiac 2Department of Anesthesiology and Critical Care Medicine, Clinical and Edu- arrest [1]. It does not often cause severe hypoxemia in the patient, and cational Training Center, Tsukuba University Hospital, Japan our review of the literature revealed no previous reports of such cases that cause of the laryngospasm was the removal of nasogastric tube. Here, we describe this significant adverse event in a case and suggest Abstract ways to lessen the possibility of its occurrence. We obtained written informed consent for publication of this case report from the patient. Background: We report a case of laryngospasm during nasogastric tube removal. Laryngospasm is a severe airway complication after Case report surgery and there have been no reports associated with the removal of nasogastric tubes. A 54-year-old woman height, 157 cm; weight, 61 kg underwent abdominal surgery (partial hepatectomy with right partial Case Report: After abdominal surgery, the patient was extubated the tracheal tube, and was removed the nasogastric tube.
    [Show full text]
  • Infectious Waste Contingency Plan
    Infectious Waste Contingency Plan Office of Environmental Health and Safety January 2012 Table of Contents I. Introduction……………………………………………………………………………..3 II. Facility Identification…………………………………………………………………..3 III. Emergency Contacts………………………………………………………………...3-4 IV. Scope and Responsibilities……………………………………………………………5 V. Infectious Waste Defined………………………………………….…………………...5 VI. Procedures for Infectious Waste Generators…………………………….………….5-6 VII. Infectious Waste Storage – EHS…………………………………………………......7 VIII. Infectious Waste Disposal – EHS…………………………………………………7-8 IX. Autoclaving – BGES…………………………………………………………………..8 X. Spill Containment and Cleanup Procedures…………………………………………8-10 XI. Training……………………………………………………………………………......10 XII. Records………………………………………………………………………………..11 XIII. Contingency for Disposal…………………………………………………………….11 Appendix A – Definitions……………………………………………………………...12-13 Appendix B – “Sharps” Management……………………………………………………...14 Appendix C – Infectious Waste Inventory Form……………………………………….15-16 Appendix D – Infectious Waste Storage Area Inspection Form………………………..17-18 Appendix E – Spill Log Form…………………………………………………………..19-20 2 I. Introduction In accordance with amendments set forth by the Ohio Environmental Protection Agency (OEPA) to the Ohio Administrative Code (OAC) Chapter 3745, Cleveland State University has declared itself a large quantity generator of infectious waste (generates greater than fifty or more pounds of infectious waste per month) and has developed this Infectious Waste Contingency Plan in order to comply with the
    [Show full text]
  • Critical Care in the Monoplace Hyperbaric Chamber
    Critical Care in the Monoplace Hyperbaric Critical Care - Monoplace Chamber • 30 minutes, so only key points • Highly suggest critical care medicine is involved • Pitfalls Lindell K. Weaver, MD Intermountain Medical Center Murray, Utah, and • Ventilator and IV issues LDS Hospital Salt Lake City, Utah Key points Critical Care in the Monoplace Chamber • Weaver LK. Operational Use and Patient Care in the Monoplace Chamber. In: • Staff must be certified and experienced Resp Care Clinics of N Am-Hyperbaric Medicine, Part I. Moon R, McIntyre N, eds. Philadelphia, W.B. Saunders Company, March, 1999: 51-92 in CCM • Weaver LK. The treatment of critically ill patients with hyperbaric oxygen therapy. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, and Donovan JW, • Proximity to CCM services (ed). Critical care toxicology: diagnosis and management of the critically poisoned patient. Philadelphia: Elsevier Mosby; 2005:181-187. • Must have study patient in chamber • Weaver, LK. Critical care of patients needing hyperbaric oxygen. In: Thom SR and Neuman T, (ed). The physiology and medicine of hyperbaric oxygen therapy. quickly Philadelphia: Saunders/Elsevier, 2008:117-129. • Weaver LK. Management of critically ill patients in the monoplace hyperbaric chamber. In: Whelan HT, Kindwall E., Hyperbaric Medicine Practice, 4th ed.. • CCM equipment North Palm Beach, Florida: Best, Inc. 2017; 65-95. • Without certain modifications, treating • Gossett WA, Rockswold GL, Rockswold SB, Adkinson CD, Bergman TA, Quickel RR. The safe treatment, monitoring and management
    [Show full text]
  • Supplementary Material
    Supplementary material Table S1. Search strategy performed on the following databases: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL). 1. Randomi*ed study OR random allocation OR Randomi*ed controlled trial OR Random* Control* trial OR RCT Epidemiological study 2. sodium glucose cotransporter 2 OR sodium glucose cotransporter 2 inhibitor* OR sglt2 inhibitor* OR empagliflozin OR dapagliflozin OR canagliflozin OR ipragliflozin OR tofogliflozin OR ertugliflozin OR sotagliflozin OR sergliflozin OR remogliflozin 3. 1 AND 2 1 Table S2. Safety outcomes of empagliflozin and linagliptin combination therapy compared with empagliflozin or linagliptin monotherapy in treatment naïve type 2 diabetes patients Safety outcome Comparator 1 Comparator 2 I2 RR [95% CI] Number of events Number of events / / total subjects total subjects i. Empagliflozin + linagliptin vs empagliflozin monotherapy Empagliflozin + Empagliflozin linagliptin monotherapy ≥ 1 AE(s) 202/272 203/270 77% 0.99 [0.81, 1.21] ≥ 1 drug-related 37/272 38/270 0% 0.97 [0.64, 1.47] AE(s) ≥ 1 serious AE(s) 13/272 19/270 0% 0.68 [0.34, 1.35] Hypoglycaemia* 0/272 5/270 0% 0.18 [0.02, 1.56] UTI 32/272 25/270 29% 1.28 [0.70, 2.35] Events suggestive 12/272 13/270 9% 0.92 [0.40, 2.09] of genital infection i. Empagliflozin + linagliptin vs linagliptin monotherapy Empagliflozin + Linagliptin linagliptin monotherapy ≥ 1 AE(s) 202/272 97/135 0% 1.03 [0.91, 1.17] ≥ 1 drug-related 37/272 17/135 0% 1.08 [0.63, 1.84] AE(s) ≥ 1 serious AE(s) 13/272 2/135 0% 3.22 [0.74, 14.07] Hypoglycaemia* 0/272 1/135 NA 0.17 [0.01, 4.07] UTI 32/272 12/135 0% 1.32 [0.70, 2.49] Events suggestive 12/272 4/135 0% 1.45 [0.47, 4.47] of genital infection RR, relative risk; AE, adverse event; UTI, urinary tract infection.
    [Show full text]
  • Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Summary of investigation results Sodium-glucose co-transporter 2 (SGLT2) inhibitors September 15, 2015 Non-proprietary name a. Canagliflozin hydrate b. Dapagliflozin propylene glycolate hydrate c. Empagliflozin d. Ipragliflozin L-proline e. Luseogliflozin hydrate f. Tofogliflozin hydrate Brand name (Marketing authorization holder) a. Canaglu Tablets 100 mg (Mitsubishi Tanabe Pharma Corporation) b. Forxiga Tablets 5 mg and 10 mg (AstraZeneca K.K.) c. Jardiance Tablets 10 mg and 25 mg (Nippon Boehringer Ingelheim Co., Ltd.) d. Suglat Tablets 25 mg and 50 mg (Astellas Pharma Inc.) e. Lusefi Tablets 2.5 mg and 5 mg (Taisho Pharmaceutical Co., Ltd.) f. Apleway Tablets 20 mg (Sanofi K.K.) and Deberza Tablets 20 mg (Kowa Company, Ltd.) Indications Type 2 diabetes mellitus Summary of revision 1. Precautions regarding ketoacidosis should be added in the Important Precautions section for the above products from a to f. 2. “Ketoacidosis” should be newly added in the Clinically significant adverse reaction section for the above products from a to f. 3. “Sepsis” should be added to the “Pyelonephritis” subsection in the Important Precautions section for the above products from a to f. Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users.
    [Show full text]
  • Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats
    Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats Tatsuroh Dabasaki, Masato Shimojo, Hiroshi Ishikawa and Akio Uemura Fuji Central Research Laboratory, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, Shizuoka 412, Japan Received December 19, 1991 Accepted February 17, 1992 ABSTRACT-The anti-hypotensive effects of M6434 were evaluated and compared with those of other orally active sympathomimetics in rats. Oral administration of M6434 (0.5-2.0 mg/kg) and midodrine (1.0 5.0 mg/kg) also produced a dose-related increase in mean arterial pressure in normotensive rats. The pressor effect of M6434 was about 4 times more potent than that of midodrine. Both M6434 and midodrine caused a dose-dependent decrease in heart rate. The pressor effect of M6434 (1.0 mg/kg) did not diminish after its repeated administration for 7 days. The pretreatment with M6434 (0.5 1.0 mg/kg) and midodrine (2.0 5.0 mg/kg) improved the orthostatic index in the experimental model of postural hypotension in rats. The effect of M6434 on postural hypotension was about 5 times more po tent than that of midodrine. Intravenously injected M6434 (3-300pg/kg) produced a dose-dependent increase in the blood pressure of pithed rats. These results suggest that M6434 possesses a potent anti hypotensive activity which is superior to that of midodrine, and M6434 may be useful in the treatment of essential and postural hypotension. Keywords: M6434, a 1-Agonist, Midodrine, Postural hypotension, Orthostatic index M6434, 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imida in clinical therapy.
    [Show full text]
  • Natural Products As Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
    Reviews Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors Author ABSTRACT Wolfgang Blaschek Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon as well as by regulation of glu- Affiliation cose absorption, gluconeogenesis, biosynthesis and mobiliza- Formerly: Institute of Pharmacy, Department of Pharmaceu- tion of glycogen, glucose consumption in all tissues and glo- tical Biology, Christian-Albrechts-University of Kiel, Kiel, merular filtration, and reabsorption of glucose in the kidneys. Germany Glucose enters or leaves cells mainly with the help of two membrane integrated transporters belonging either to the Key words family of facilitative glucose transporters (GLUTs) or to the Malus domestica, Rosaceae, Phlorizin, flavonoids, family of sodium glucose cotransporters (SGLTs). The intesti- ‑ SGLT inhibitors, gliflozins, diabetes nal glucose absorption by endothelial cells is managed by SGLT1, the transfer from them to the blood by GLUT2. In the received February 9, 2017 kidney SGLT2 and SGLT1 are responsible for reabsorption of revised March 3, 2017 filtered glucose from the primary urine, and GLUT2 and accepted March 6, 2017 GLUT1 enable the transport of glucose from epithelial cells Bibliography back into the blood stream. DOI http://dx.doi.org/10.1055/s-0043-106050 The flavonoid phlorizin was isolated from the bark of apple Published online April 10, 2017 | Planta Med 2017; 83: 985– trees and shown to cause glucosuria. Phlorizin is an inhibitor 993 © Georg Thieme Verlag KG Stuttgart · New York | of SGLT1 and SGLT2. With phlorizin as lead compound, specif- ISSN 0032‑0943 ic inhibitors of SGLT2 were developed in the last decade and some of them have been approved for treatment mainly of Correspondence type 2 diabetes.
    [Show full text]